THE CORRELATION THE ROLE OF SUPERVISOR TAKING MEDICINE WITH THE SUCCESS OF TREATMENT OF LUNG TB IN PUBLIC HEALTH CENTER GERAK MAKMUR SAMPOLAWA, SOUTH BUTON

Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterum Tuberculosis which can spread through droplets that have been infected with TB bacilli. In 2018, there was increasing case of lung TB about 33 people (4 people is broken up treatmment and failed, 29 is healed). The purpose of this study was to determine the relationship between the assistance of taking medication with the success of the treatment of pulmonary TB patients and the relationship of mentoring for repeat treatment at the puskesmas with the success of the treatment of pulmonary TB patients at Gerak Makmur Puskesmas, Sampolawa Subdistrict, South Buton District. This type of research is quantitative research using cross sectional design. The number of samples in this study were 33 people. Sampling in this study uses total sampling, which is the sample taken entirely from the population who finished treatment at the prosperous Gerak Community Health Center. Data analysis performed was univariate and bivariate analysis with chi square test. The results showed that there was a relationship between the role of the supervisor of taking drugs with the success of pulmonary TB treatment in the working area of Gerak Makmur Selatan Buton South Puskesmas with a value (p = 0,000<0,05) and there is a relationship between medical assistance and the success of pulmonary TB treatment in the working area of Gerak Makmur Selatan Buton Puskesmas with a value (p = 0.008<0,05). shows that there is a relationship between the role of the supervisor of taking drugs with the success of pulmonary TB treatment and there is a relationship between the assistance of taking drugs with the success of pulmonary TB treatment, and there is a relationship between mentoring repeat treatment with the success of pulmonary TB treatment at Gerak Makmur Selatan Buton Selatan health center.Keywoard: pulmonary TB successful treatment, supervision of taking medication

Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory

Objective: To study the efficacy and safety of repeat transarterial radioembolization (TARE) to similar hepatic arterial territories. Methods: Between 3/2011 and 4/2019, 26 patients (25 males and 1 Female, Mean Age: 65 yo, SD: 11.7 yo, Range: 18–83.0 yo) received TARE with Y90 glass microspheres to treat recurrent or residual primary disease in similar hepatic arterial lobe or segments. Tumor response was evaluated by imaging using the modified-RECIST criteria. Incidence of RILD and adverse events were categorized by a standardized scale using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. Results: Mean cumulative activity after the first treatment was 2.50 GBq (SD:1.04 GBq, Range:0.61–4.93 GBq) and second treatment was 2.27 GBq (SD:1.01 GBq, Range:0.92–5.46 GBq). Mean interval time between initial and repeat treatments was 9.6 months (Range: 1–53 months). Tumor responses were complete, partial, or progression in 73% (n = 19/26), 23% (n = 6/26), and 4% (n = 1/26) in repeat treatment patients, respectively. The incidence of RILD was 0%. Toxicity after first and second treatment was seen in 19% (n = 5/26) & 23% (n = 6/26) patients, respectively, and were all of CTCAE Grade 2. No significant predictors of treatment toxicity for repeat treatment were identified except increased MELD score (p = 0.04). Kaplan-Meier survival analysis in patients with repeat treatment showed a median survival of 15.0 months (95% CI 8.8–21.1 months) and 19.0 months (95% CI 8.1–29.9 months) in patients who only received one treatment with a p value of 0.485. Conclusion: Repeat TARE with glass microspheres was an effective and safe treatment strategy for disease management in patients with residual or recurrent disease to the similar hepatic arterial territories without any major treatment related toxicity. Advances in knowledge: Although safety and efficacy of repeat radioembolism has been studied, no study has focused on repeat treatment to similar hepatic arterial territories. The current study shows that repeat treatment to the same hepatic arterial territory is as safe as single treatment to the same territory.

An Audit of IO6 YAG Laser Capsulotomies Done between January 2017 - December 2017 in St. Joseph Eye Hospital, Mgbirichi, Owerri, Imo State and Viandra Eye Clinic, Port Harcourt, Rivers State of Nigeria

Aim: To audit the YAG Laser Capsulotomy procedures done over a 12 month period from January to December 2017. Objective: To review YAG LASER capsulotomies done over a 12 months period from January 2017 – December 2017. Methods: The audit was retrospective in nature, involving collation of parameters such as age, sex, presenting visual acuity, post laser visual acuity, complications and post operative management from the patient records. The lasers were performed with SYL 9000 Ophthalmic yttrium aluminum garnet (YAG) Laser systems [Lightmed Corporation, Taiwan]. This is a class 3b Laser with a wavelength of 1064 nm and Q-switched operational mode and a spot size of 8 um. Results: The audit involved 106 subjects. The mean age was 56.76 years. Fifty nine (55.7%) subjects were females while 44.3% were males. Eleven (10.4%) subjects had bilateral neodymium‐doped yttrium aluminum garnet ND YAG laser treatment while 89.6% had unilateral treatment. Seventy five (72.8%) of the subjects had visual improvement following treatment. Seventy four (69.8%) had less than 3 mJ quantum of energy and only 5.7% required repeat treatment. Fifty (47.2%) had between one to three days post op treatment with anti-inflammatory and/or pressure reducing drugs. Conclusion: Use of low energy in ND YAG laser treatment of Posterior Capsule Opacification offers good visual outcome, precludes the complication associated with higher energy treatment and does not necessarily lead to repeat treatment.

VYC-25L Hyaluronic Acid Injectable Gel Is Safe and Effective for Long-Term Restoration and Creation of Volume of the Lower Face

Background Juvéderm Volux (VYC-25L; Allergan plc) is an injectable hyaluronic acid gel designed to restore and create facial volume. Objective The aim of this study was to evaluate the safety and effectiveness of Volux for chin retrusion over 18 months and after repeat treatment. Methods This prospective, single-blind, controlled study enrolled subjects aged ≥18 years with chin retrusion (glabella-subnasale-pogonion facial angle 145°-165°). Subjects were randomized (3:1) to Volux at study onset or 3 months later (control group), and could receive a single repeat treatment during months 18 to 24. Assessments included mean facial-angle change from baseline, Global Aesthetic Improvement Scale (GAIS) responder rates (improved/much improved), improvements in 3 subject-reported FACE-Q scales, and safety. Results Of 132 enrolled subjects, 119 received initial Volux treatment and 89 received repeat treatment. Mean changes (95% confidence interval) in glabella-subnasale-pogonion angle from baseline for treatment and control groups, respectively, were: 1.15° (0.75°, 1.56°) and 1.16° (0.57°, 1.75°) at month 18, and 3.14° (2.68°, 3.61°) and 2.72° (1.78°, 3.66°) 1 month after repeat treatment. Investigators rated 52.5%/60.0% of treated/control subjects at month 18 and 96.9%/100% after retreatment as GAIS responders; subject-reported rates were 62.0%/64.0% and 93.8%/100%. Durable improvements in Satisfaction with Chin, Satisfaction with Lower Face and Jawline, and Psychological Well-Being were reported in 82.1%, 78.2%, and 60.3% of subjects, respectively, at month 18, and 92.3%, 93.8%, and 67.7% of subjects after retreatment. The safety profile was as expected. Conclusions Volux injectable gel is a safe, effective, and durable alternative to surgical treatments for increasing chin projection and jaw volume, and results in high patient satisfaction. Level of Evidence: 2

Persistent eosinophilia among 21 historic cases of Strongyloides stercoralis infection: a case for routine follow-up and repeat treatment

Background Strongyloidasis affects more than 100 million people worldwide and causes persisting infection. Methods We retrospectively reviewed 21 cases of parasitologically confirmed Strongyloides stercoralis infection at our centre. Results We found four individuals who had eosinophilia (>0.5x109/litre) more than 6 mo after treatment. Conclusions This may represent ongoing or relapsed infection. Our data support the need for continued follow-up of treated individuals, particularly those with abnormal host defences who are at risk of severe forms of the disease.

Safety and Effectiveness of VYC-17.5L for Long-Term Correction of Nasolabial Folds

Background Juvéderm Vollure XC (VYC-17.5L; Allergan plc, Dublin, Ireland) belongs to a family of hyaluronic acid gels based on the Vycross technology platform. Objectives The authors sought to evaluate the safety and effectiveness of Vollure for correction of moderate to severe nasolabial folds (NLFs) over 18 months and after repeat treatment. Methods In this prospective, randomized study, patients (N = 123) received initial/touch-up treatment with Vollure in 1 NLF and control filler in the contralateral NLF. Patients received optional repeat treatment with Vollure after month 12, 15, or 18. Assessments included investigator-rated NLF Severity Scale responder rates (≥1-point improvement vs baseline), patient-assessed Appraisal of Nasolabial Folds scale of the FACE-Q questionnaire, and patient satisfaction (11-point scale). Results Median volume of Vollure injected was 1.7 mL for initial/touch-up treatment combined and 0.6 mL for repeat treatment. The NLF Severity Scale responder rates were 93%, 85%, and 59% at months 6, 9, and 18 after initial/touch-up treatment and increased to 94% at 1 month after repeat treatment. Mean patient-reported FACE-Q scores significantly improved from baseline at all timepoints. Most patients were very satisfied with treatment at all timepoints from day 3 (75%) through month 18 (68%) and at 1 month after repeat treatment (94%). Common injection site responses after initial/touch-up and repeat treatment were firmness, swelling, and tenderness to touch; most were mild/moderate. Conclusions Vollure was safe and effective for correction of moderate to severe NLFs, with results lasting 18 months in 59% of NLFs. Repeat treatment required one-third of the injection volume to achieve similar improvement in NLF severity as initial/touch-up treatment. Level of Evidence: 2